BAM-15 Dosage Guide, Benefits & Side Effects

In animal studies, BAM-15's plasma half-life is short (on the order of a few hours), but its effect on mitochondrial respiration appears to last considerably longer — reportedly over 12 hours — due to the compound's retention within the inner mitochondrial membrane. This means blood levels dropping quickly does not necessarily mean the metabolic effect has ended.

In rodent studies, BAM-15 has not produced the hyperthermia seen with older uncouplers like DNP, and did not reduce food intake or cause obvious toxicity at tested doses. That said, there is no published human safety data. Unknowns include potential drug interactions, effects on thyroid or hormonal regulation, cardiovascular effects, and long-term consequences for mitochondrial function. People with thyroid disorders, cardiovascular disease, or diabetes on medication are frequently flagged in discussions as facing unknown additional risk. Any use in humans is considered experimental.

BAM-15 is not approved by the FDA or any regulatory agency for human consumption. It is sold by research chemical suppliers labeled 'for research purposes only, not for human use.' It has also been added to anti-doping prohibited-substance lists (WADA's metabolic modulator category), meaning athletes subject to drug testing can be sanctioned if it is detected, regardless of intent.

Unlike many injectable peptides, BAM-15 is an orally active small molecule. Vendors commonly sell it as raw powder or in pre-made oral capsules, and it does not require reconstitution with bacteriostatic water or injection equipment. This is a practical distinction from injectable peptides, though it does not change its regulatory or safety status as an unapproved research compound.